<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">hepato</journal-id><journal-title-group><journal-title xml:lang="ru">Анналы хирургической гепатологии</journal-title><trans-title-group xml:lang="en"><trans-title>Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-5464</issn><issn pub-type="epub">2408-9524</issn><publisher><publisher-name>НЭИКОН ИСП</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.16931/1995-5464.2020267-76</article-id><article-id custom-type="elpub" pub-id-type="custom">hepato-618</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ГЕПАТОЦЕЛЛЮРНЫЙ РАК. ДИАГНОСТИКА И ЛЕЧЕНИЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>HEPATOCELLULAR CARCINOMA: DIAGNOSIS AND TREATMENT</subject></subj-group></article-categories><title-group><article-title>Результаты трансплантации печени при гепатоцеллюлярном раке: опыт одного центра</article-title><trans-title-group xml:lang="en"><trans-title>Outcomes of liver transplantation in hepatocellular carcinoma: a single-center experience</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0633-678X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Готье</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gautier</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Готье Сергей Владимирович – доктор медицинских наук, профессор, академик РАН, Заслуженный врач Российской Федерации, директор ФГБУ “НМИЦ ТИО им. академика В.И. Шумакова” Минздрава России, заведующий кафедрой трансплантологии и искусственных органов Сеченовского Университета</p><p>123182, г. Москва, ул. Щукинская, д. 1, </p><p>119991, Москва, ул. Трубецкая, д.8, стр. 2</p></bio><bio xml:lang="en"><p>Sergey V. Gautier – Doct. of Sci. (Med.), Professor, Corresponding Member of the Russiаn Асаdemy of Sсienсes, Director of the Shumakov National Medical Research Center of Transplantology and Artificial Organs, Head of the Department of Transplantology and Artificial Organs of the Sechenov University</p><p>1, Shukinskaya str., Moscow, 123182, </p><p>8, b. 2, Trubetskaya str., Moscow, 119991</p></bio><email xlink:type="simple">gautier@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3537-6601</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Монахов</surname><given-names>А. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Monakhov</surname><given-names>A. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Монахов Артем Рашидович – кандидат медицинских наук, заведующий хирургическим отделением №2 (трансплантация печени) ФГБУ “НМИЦ ТИО им. академика В.И. Шумакова” Минздрава России; ассистент кафедры трансплантологии и искусственных органов Сеченовского Университета</p><p>123182, г. Москва, ул. Щукинская, д. 1, </p><p>119991, Москва, ул. Трубецкая, д.8, стр. 2</p></bio><bio xml:lang="en"><p>Artem R. Monakhov – Cand. of Sci. (Med), Head of the Surgical Department №2 (Liver Transplantation) of the Shumakov National Medical Research Center of Transplantology and Artificial Organs</p><p>1, Shukinskaya str., Moscow, 123182, </p><p>8, b. 2, Trubetskaya str., Moscow, 119991</p></bio><email xlink:type="simple">a.r.monakhov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цирульникова</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsirulnikova</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Цирульникова Ольга Мартеновна – доктор медицинских наук, профессор кафедры трансплантологии и искусственных органов</p><p>119991, Москва, ул. Трубецкая, д.8, стр. 2</p></bio><bio xml:lang="en"><p>Olga M. Tsirulnikova – Doct. of Sci. (Med.), Professor of the Department of Transplantation and Artificial Organs</p><p>8, b. 2, Trubetskaya str., Moscow, 119991</p><p> </p></bio><email xlink:type="simple">tsiroulnikova@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5436-7092</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зубенко</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Zubenko</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зубенко Степан Игоревич – врач-хирург хирургического отделения №2</p><p>123182, г. Москва, ул. Щукинская, д. 1</p></bio><bio xml:lang="en"><p>Stepan I. Zubenko – Surgeon of Surgical Department No.2</p><p>1, Shukinskaya str., Moscow, 123182</p></bio><email xlink:type="simple">stepanzubenko@yahoo.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0698-2191</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ситникова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sitnikova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ситникова Екатерина Васильевна – врач-терапевт терапевтического отделения</p><p>123182, г. Москва, ул. Щукинская, д. 1</p></bio><bio xml:lang="en"><p>Ekaterina V. Sitnikova – Physician of Therapy Department</p><p>1, Shukinskaya str., Moscow, 123182</p></bio><email xlink:type="simple">kath1een@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3130-2119</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Умрик</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Umrik</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Умрик Дарья Валентиновна – кандидат медицинских наук, заведующий терапевтическим отделением</p><p>123182, г. Москва, ул. Щукинская, д. 1</p></bio><bio xml:lang="en"><p>Daria V. Umrik – Cand. of Sci. (Med.), Head of Therapy Department</p><p>1, Shukinskaya str., Moscow, 123182</p></bio><email xlink:type="simple">d_ipatova@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8642-0756</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Носов</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nosov</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Носов Кирилл Анатольевич – клинический ординатор хирургического отделения №2</p><p>123182, г. Москва, ул. Щукинская, д. 1</p></bio><bio xml:lang="en"><p>Kirill A. Nosov – Resident of the Surgical Department No.2</p><p>1, Shukinskaya str., Moscow, 123182</p></bio><email xlink:type="simple">Hellawaits11@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8615-3742</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куртак</surname><given-names>Н. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurtak</surname><given-names>N. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Куртак Никита Дмитриевич – клинический ординатор хирургического отделения №2</p><p>123182, г. Москва, ул. Щукинская, д. 1</p></bio><bio xml:lang="en"><p>Nikita D. Kurtak – Resident of the Surgical Department No.2</p><p>1, Shukinskaya str., Moscow, 123182</p></bio><email xlink:type="simple">Dr.kurtak@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ “НМИЦ трансплантологии и искусственных органов им. академика В.И. Шумакова” Минздрава России;&#13;
ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Shumakov National Medical Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation;&#13;
Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ “НМИЦ трансплантологии и искусственных органов им. академика В.И. Шумакова” Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Shumakov National Medical Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>27</day><month>04</month><year>2020</year></pub-date><volume>25</volume><issue>2</issue><fpage>67</fpage><lpage>76</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Готье С.В., Монахов А.Р., Цирульникова О.М., Зубенко С.И., Ситникова Е.В., Умрик Д.В., Носов К.А., Куртак Н.Д., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Готье С.В., Монахов А.Р., Цирульникова О.М., Зубенко С.И., Ситникова Е.В., Умрик Д.В., Носов К.А., Куртак Н.Д.</copyright-holder><copyright-holder xml:lang="en">Gautier S.V., Monakhov A.R., Tsirulnikova O.M., Zubenko S.I., Sitnikova E.V., Umrik D.V., Nosov K.A., Kurtak N.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://hepato.elpub.ru/jour/article/view/618">https://hepato.elpub.ru/jour/article/view/618</self-uri><abstract><sec><title>Цель</title><p>Цель. Оценить отдаленные результаты трансплантации печени при гепатоцеллюлярном раке, провести анализ факторов риска рецидива опухоли.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Проведен ретроспективный анализ 63 трансплантаций печени от посмертного донора с января 2010 по февраль 2020 г. Пациенты разделены на три группы по соответствию Миланским и Калифорнийским критериям – в пределах Миланских критериев, за пределами Миланских критериев, но в пределах Калифорнийских критериев, за пределами Калифорнийских критериев.</p></sec><sec><title>Результаты</title><p>Результаты. В рамках Миланских критериев было 33 реципиента, в рамках Калифорнийских критериев – 5, вне Калифорнийских критериев – 25. Частота рецидива рака в течение пяти лет наблюдения составила 9,1, 40 и 52% соответственно (p = 0,002), пятилетняя выживаемость – 93,2, 66,7 и 54,7% (p = 0,041). Факторы, ассоциированные с повышенным риском рецидива: ≥5 опухолевых узлов (ОР = 3,675; 95% ДИ (1,35–9,97); p = 0,011), макрососудистая инвазия (ОР = 5,97; 95% ДИ (2,06–17,31); p = 0,001) и несоответствие Калифорнийским критериям (ОР = 4,00; 95% ДИ (1,49–10,74); p = 0,006). Факторы, ассоциированные с меньшей частотой рецидива: 1–2 опухолевых узла (p = 0,014 и 0,042 соответственно), высокая степень гистологической дифференцировки (ОР = 0,24; 95% ДИ (0,06–0,93); p = 0,039), соответствие Миланским критериям (ОР = 0,18; 95% ДИ (0,06–0,58); p = 0,004).</p></sec><sec><title>Заключение</title><p>Заключение. Трансплантация печени может быть выполнена ряду пациентов, не соответствующих Миланским и Калифорнийским критериям. Важную роль в успехе лечения играют морфологические и биологические характеристики опухоли, дифференцированный мультидисциплинарный подход к лечению.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To evaluate the long-term results of liver transplantation for hepatocellular carcinoma. To perform an analysis of risk factors for tumor recurrence.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A retrospective analysis of 63 deceased donor liver transplantations, which were performed from January 2010 to February 2020. Patients were divided into three groups according to the Milan and California criteria – within the Milan criteria, outside the Milan criteria, but within the California criteria, outside the California criteria.</p></sec><sec><title>Results</title><p>Results. There were 33 recipients within the Milan criteria, 5 within the California criteria, and 25 outside the California criteria. The 5-years recurrence rate was 9.1%, 40% and 52%, respectively (p = 0.002), five-year survival rate of – 93.2%, 66.7% and 54.7% (p = 0.041). Factors associated with an increased risk of recurrence: five and more tumor nodes (OR = 3.675; 95% CI (1.35–9.97); p = 0.011), macroscopic vascular invasion (OR = 5.97; 95% CI (2.06–17.31); p = 0.001) and inconsistency with California criteria (OR = 4.00; 95% CI (1.49–10.74); p = 0.006). The factors associated with a lower recurrence rate: one or two tumor nodes (p = 0.014 and 0.042, respectively), a high grade of histological differentiation (RR = 0.24; 95% CI (0.06–0.93); p = 0.039), compliance with Milanese criteria (RR = 0.18; 95% CI (0.06–0.58); p = 0.004).</p></sec><sec><title>Conclusion</title><p>Conclusion. Liver transplantation can be performed in a number of patients beyond the Milan and California criteria. The morphological and biological characteristics of the tumor and a multidisciplinary differentiated approach to treatment have an important role in the success of treatment.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>печень</kwd><kwd>гепатоцеллюлярный рак</kwd><kwd>трансплантация</kwd><kwd>Миланские критерии</kwd><kwd>Калифорнийские критерии</kwd><kwd>отдаленные результаты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>liver</kwd><kwd>hepatocellular carcinoma</kwd><kwd>liver transplantation</kwd><kwd>Milan criteria</kwd><kwd>California criteria</kwd><kwd>long-term results</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Waller L.P., Deshpande V., Pyrsopoulos N. Hepato cellular carcinoma: A comprehensive review. World J. Hepatol. 2015; 7 (26): 2648–2663. https://doi.org/10.4254/wjh.v7.i26.2648</mixed-citation><mixed-citation xml:lang="en">Waller L.P., Deshpande V., Pyrsopoulos N. Hepato cellular carcinoma: A comprehensive review. World J. Hepatol. 2015; 7 (26): 2648–2663. https://doi.org/10.4254/wjh.v7.i26.2648</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бредер В.В., Косырев С.Ю., Кудашкин Н.Е., Лактионов К.К. Гепатоцеллюлярный рак в Российской Федерации как социальная и медицинская проблема. Медицинский Совет. 2016; 10: 10–18. https://doi.org/10.21518/2079-701X-2016-10-10-18</mixed-citation><mixed-citation xml:lang="en">Breder V.V., Kosyrev V.Y., Kudashkin N.E., Laktionov K.K. Hepatocellular carcinoma as a social and medical problem in the Russian Federation. Meditsinskiy sovet = Medical Council. 2016; 10: 10–18. https://doi.org/10.21518/2079-701X-2016-10-10-18 (In Russian)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Perini M.V., Starkey G., Fink M.A., Bhandari R., Muralid haran V., Jones R., Christophi C. From minimal to maximal surgery in the treatment of hepatocarcinoma: A review. World J. Hepatol. 2015; 7 (1): 93–100. https://doi.org/10.4254/wjh.v7.i1.93</mixed-citation><mixed-citation xml:lang="en">Perini M.V., Starkey G., Fink M.A., Bhandari R., Muralid haran V., Jones R., Christophi C. From minimal to maximal surgery in the treatment of hepatocarcinoma: A review. World J. Hepatol. 2015; 7 (1): 93–100. https://doi.org/10.4254/wjh.v7.i1.93</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19 (3): 329–338. https://doi.org/10.1055/s-2007-1007122</mixed-citation><mixed-citation xml:lang="en">Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19 (3): 329–338. https://doi.org/10.1055/s-2007-1007122</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Yang J.D., Hainaut P., Gores G.J., Amadou A., Plymoth A., Roberts L.R. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 2019; 16 (10): 589–604. https://doi.org/10.1038/s41575-019-0186-y.</mixed-citation><mixed-citation xml:lang="en">Yang J.D., Hainaut P., Gores G.J., Amadou A., Plymoth A., Roberts L.R. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 2019; 16 (10): 589–604. https://doi.org/10.1038/s41575-019-0186-y.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Raza A., Sood G.K. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J. Gastroenterol. 2014; 20 (15): 4115–4127. https://doi.org/10.3748/wjg.v20.i15.4115</mixed-citation><mixed-citation xml:lang="en">Raza A., Sood G.K. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J. Gastroenterol. 2014; 20 (15): 4115–4127. https://doi.org/10.3748/wjg.v20.i15.4115</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kow A.W.C. Transplantation versus liver resection in patients with hepatocellular carcinoma. Transl. Gastroenterol. Hepatol. 2019; 4: 33. https://doi.org/10.21037/tgh.2019.05.06</mixed-citation><mixed-citation xml:lang="en">Kow A.W.C. Transplantation versus liver resection in patients with hepatocellular carcinoma. Transl. Gastroenterol. Hepatol. 2019; 4: 33. https://doi.org/10.21037/tgh.2019.05.06</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kumari R., Sahu M.K., Tripathy A., Uthansingh K., Behera M. Hepatocellular carcinoma treatment: hurdles, advances and prospects. Hepat. Oncol. 2018; 5 (2): HEP08. Published 2018 Sep 28. https://doi.org/10.2217/hep-2018-0002</mixed-citation><mixed-citation xml:lang="en">Kumari R., Sahu M.K., Tripathy A., Uthansingh K., Behera M. Hepatocellular carcinoma treatment: hurdles, advances and prospects. Hepat. Oncol. 2018; 5 (2): HEP08. Published 2018 Sep 28. https://doi.org/10.2217/hep-2018-0002</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Xu D.W., Wan P., Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J. Gastroenterol. 2016; 22 (12): 3325–3334. https://doi.org/10.3748/wjg.v22.i12.</mixed-citation><mixed-citation xml:lang="en">Xu D.W., Wan P., Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J. Gastroenterol. 2016; 22 (12): 3325–3334. https://doi.org/10.3748/wjg.v22.i12.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrer-Fàbrega J., Forner A., Liccioni A., Miquel R., Molina V., Navasa M., Fondevila C., García-Valdecasas J.C., Bruix J., Fuster J. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology. 2016; 63 (3): 839– 849. https://doi.org/10.1002/hep.28339</mixed-citation><mixed-citation xml:lang="en">Ferrer-Fàbrega J., Forner A., Liccioni A., Miquel R., Molina V., Navasa M., Fondevila C., García-Valdecasas J.C., Bruix J., Fuster J. Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Hepatology. 2016; 63 (3): 839– 849. https://doi.org/10.1002/hep.28339</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kakodkar R., Soin A.S. Liver Transplantation for HCC: A Review. Indian J. Surg. 2012; 74 (1): 100–117. https://doi.org/10.1007/s12262-011-0387-2</mixed-citation><mixed-citation xml:lang="en">Kakodkar R., Soin A.S. Liver Transplantation for HCC: A Review. Indian J. Surg. 2012; 74 (1): 100–117. https://doi.org/10.1007/s12262-011-0387-2</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Charrière B., Maulat C., Suc B., Muscari F. Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World J. Hepatol. 2016; 8 (21): 881–890. https://doi.org/10.4254/wjh.v8.i21.881</mixed-citation><mixed-citation xml:lang="en">Charrière B., Maulat C., Suc B., Muscari F. Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World J. Hepatol. 2016; 8 (21): 881–890. https://doi.org/10.4254/wjh.v8.i21.881</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y., Shen Z., Zhu Z., Han R., Huai M. Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepat. Mon. 2011; 11 (3): 195–199. PMCID: PMC3206678.</mixed-citation><mixed-citation xml:lang="en">Wang Y., Shen Z., Zhu Z., Han R., Huai M. Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepat. Mon. 2011; 11 (3): 195–199. PMCID: PMC3206678.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Choi H.J., Kim D.G., Na G.H., Han J.H., Hong T.H., You Y.K. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation. World J. Gastroenterol. 2013; 19 (29): 4737–4744. https://doi.org/10.3748/wjg.v19.i29.4737</mixed-citation><mixed-citation xml:lang="en">Choi H.J., Kim D.G., Na G.H., Han J.H., Hong T.H., You Y.K. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation. World J. Gastroenterol. 2013; 19 (29): 4737–4744. https://doi.org/10.3748/wjg.v19.i29.4737</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Colhoun E.D. 5th, Forsberg C.G., Chavin K.D., Baliga P.K., Taber D.J. Incidence and risk factors of hepatocellular carcinoma after orthotopic liver transplantation. Surgery. 2017; 161 (3): 830–836. https://doi.org/10.1016/j.surg.2016.08.049</mixed-citation><mixed-citation xml:lang="en">Colhoun E.D. 5th, Forsberg C.G., Chavin K.D., Baliga P.K., Taber D.J. Incidence and risk factors of hepatocellular carcinoma after orthotopic liver transplantation. Surgery. 2017; 161 (3): 830–836. https://doi.org/10.1016/j.surg.2016.08.049</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Schraiber Ldos. S., de Mattos A.A., Zanotelli M.L., Cantisani G.P., Brandão A.B., Marroni C.A., Kiss G., Ernani L., MarconPdos. S. Alpha-fetoprotein level predicts recurrence after transplantation in hepatocellular carcinoma. Medicine (Baltimore). 2016; 95 (3): e2478. https://doi.org/10.1097/MD.0000000000002478</mixed-citation><mixed-citation xml:lang="en">Schraiber Ldos. S., de Mattos A.A., Zanotelli M.L., Cantisani G.P., Brandão A.B., Marroni C.A., Kiss G., Ernani L., MarconPdos. S. Alpha-fetoprotein level predicts recurrence after transplantation in hepatocellular carcinoma. Medicine (Baltimore). 2016; 95 (3): e2478. https://doi.org/10.1097/MD.0000000000002478</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Saitta C., Raffa G., Alibrandi A., Brancatelli S., Lombardo D., Tripodi G., Raimondo G., Pollicino T. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine (Baltimore). 2017; 96 (26): e7266. https://doi.org/10.1097/MD.0000000000007266</mixed-citation><mixed-citation xml:lang="en">Saitta C., Raffa G., Alibrandi A., Brancatelli S., Lombardo D., Tripodi G., Raimondo G., Pollicino T. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine (Baltimore). 2017; 96 (26): e7266. https://doi.org/10.1097/MD.0000000000007266</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson P.J. The BALAD-2 and GALAD Biomarker models for hepatocellular carcinoma. Gastroenterol. Hepatol. (NY). 2017; 13 (4): 231–233. PMID: 28546794; PMCID: PMC5441024.</mixed-citation><mixed-citation xml:lang="en">Johnson P.J. The BALAD-2 and GALAD Biomarker models for hepatocellular carcinoma. Gastroenterol. Hepatol. (NY). 2017; 13 (4): 231–233. PMID: 28546794; PMCID: PMC5441024.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Akateh C., Black S.M., Conteh L., Miller E.D., Noonan A., Elliott E., Pawlik T.M., Tsung A., Cloyd J.M. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J. Gastroenterol. 2019; 25 (28): 3704–3721. https://doi.org/10.3748/wjg.v25.i28.3704</mixed-citation><mixed-citation xml:lang="en">Akateh C., Black S.M., Conteh L., Miller E.D., Noonan A., Elliott E., Pawlik T.M., Tsung A., Cloyd J.M. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J. Gastroenterol. 2019; 25 (28): 3704–3721. https://doi.org/10.3748/wjg.v25.i28.3704</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Massarollo P.C., Coppini A.Z., Salzedas-Netto A.A., Coelho F.F., Minami T., Gonzalez A.M. Favorable long-term outcome in patients submitted to liver transplantation after downstaging of hepatocellular carcinoma according to a Brazilian selection protocol. Transplant. Proc. 2016; 48 (7): 2338–2340. https://doi.org/10.1016/j.transproceed.2016.06.029.</mixed-citation><mixed-citation xml:lang="en">Massarollo P.C., Coppini A.Z., Salzedas-Netto A.A., Coelho F.F., Minami T., Gonzalez A.M. Favorable long-term outcome in patients submitted to liver transplantation after downstaging of hepatocellular carcinoma according to a Brazilian selection protocol. Transplant. Proc. 2016; 48 (7): 2338–2340. https://doi.org/10.1016/j.transproceed.2016.06.029.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Yu C.Y., Ou H.Y., Huang T.L., Chen T.Y., Tsang L.L., Chen C.L., Cheng Y.F. Hepatocellular carcinoma downstaging in liver transplantation. Transplant. Proc. 2012; 44 (2): 412–414. https://doi.org/10.1016/j.transproceed.2012.01.043.</mixed-citation><mixed-citation xml:lang="en">Yu C.Y., Ou H.Y., Huang T.L., Chen T.Y., Tsang L.L., Chen C.L., Cheng Y.F. Hepatocellular carcinoma downstaging in liver transplantation. Transplant. Proc. 2012; 44 (2): 412–414. https://doi.org/10.1016/j.transproceed.2012.01.043.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Cescon M., Cucchetti A., Ravaioli M., Pinna A.D. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J. Hepatol. 2013; 58 (3): 609–618. Epub 2012 Oct 4. https://doi.org/10.1016/j.jhep.2012.09.021.</mixed-citation><mixed-citation xml:lang="en">Cescon M., Cucchetti A., Ravaioli M., Pinna A.D. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J. Hepatol. 2013; 58 (3): 609–618. Epub 2012 Oct 4. https://doi.org/10.1016/j.jhep.2012.09.021.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Finkenstedt A., Vikoler A., Portenkirchner M., Mülleder K., Maglione M., Margreiter C., Moser P., Vogel W., Bale R., Freund M., Luger A., Tilg H., Petersen J., Schneeberger S., Graziadei I., Zoller H., Glodny B. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver Int. 2016; 36 (5): 688–695. Epub 2015 Oct 12. https://doi.org/10.1111/liv.12966.</mixed-citation><mixed-citation xml:lang="en">Finkenstedt A., Vikoler A., Portenkirchner M., Mülleder K., Maglione M., Margreiter C., Moser P., Vogel W., Bale R., Freund M., Luger A., Tilg H., Petersen J., Schneeberger S., Graziadei I., Zoller H., Glodny B. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy. Liver Int. 2016; 36 (5): 688–695. Epub 2015 Oct 12. https://doi.org/10.1111/liv.12966.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Park H.W., Hwang S., Ahn C.S., Kim K.H., Moon D.B., Ha T.Y., Song G.W., Jung D.H., Park G.C., Namgoong J.M., Park C.S., Park Y.H., Kang S.H., Jung B.H., Lee S.G. Longterm survival outcomes for living donor liver transplant recipients with pathologically nonviable hepatocellular carcinoma. Transplant. Proc. 2013; 45 (8): 3032–3034. https://doi.org/10.1016/j.transproceed.2013.08.027.</mixed-citation><mixed-citation xml:lang="en">Park H.W., Hwang S., Ahn C.S., Kim K.H., Moon D.B., Ha T.Y., Song G.W., Jung D.H., Park G.C., Namgoong J.M., Park C.S., Park Y.H., Kang S.H., Jung B.H., Lee S.G. Longterm survival outcomes for living donor liver transplant recipients with pathologically nonviable hepatocellular carcinoma. Transplant. Proc. 2013; 45 (8): 3032–3034. https://doi.org/10.1016/j.transproceed.2013.08.027.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Beal E.W., Dittmar K.M., Hanje A.J., Michaels A.J., Conteh L., Davidson G., Black S.M., Bloomston P.M., Dillhoff M.E., Schmidt C.R. Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival. Front. Oncol. 2016; 6: 143. https://doi.org/10.3389/fonc.2016.00143</mixed-citation><mixed-citation xml:lang="en">Beal E.W., Dittmar K.M., Hanje A.J., Michaels A.J., Conteh L., Davidson G., Black S.M., Bloomston P.M., Dillhoff M.E., Schmidt C.R. Pretransplant Locoregional Therapy for Hepatocellular Carcinoma: Evaluation of Explant Pathology and Overall Survival. Front. Oncol. 2016; 6: 143. https://doi.org/10.3389/fonc.2016.00143</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jung E.S., Kim J.H., Yoon E.L., Lee H.J., Lee S.J., Suh S.J., Lee B.J., Seo Y.S., Yim H.J., Seo T.S., Lee C.H., Yeon J.E., Park J.J., Kim J.S., Bak Y.T., Byun K.S. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J. Hepatol. 2013; 58 (6): 1181–1187. https://doi.org/10.1016/j.jhep.2013.01.039.</mixed-citation><mixed-citation xml:lang="en">Jung E.S., Kim J.H., Yoon E.L., Lee H.J., Lee S.J., Suh S.J., Lee B.J., Seo Y.S., Yim H.J., Seo T.S., Lee C.H., Yeon J.E., Park J.J., Kim J.S., Bak Y.T., Byun K.S. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J. Hepatol. 2013; 58 (6): 1181–1187. https://doi.org/10.1016/j.jhep.2013.01.039.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Victor D.W. 3rd, Monsour H.P. Jr., Boktour M., Lunsford K., Balogh J., Graviss E.A., Nguyen D.T., McFadden R., Divatia M.K., Heyne K., Ankoma-Sey V., Egwim C., Galati J., Duchini A., Saharia A., Mobley C., Gaber A.O., Ghobrial R.M. Outcomes of liver transplantation for hepatocellular carcinoma beyond the university of California San Francisco criteria: a single-center experience. Transplantation. 2020; 104 (1): 113– 121. https://doi.org/10.1097/TP.0000000000002835.</mixed-citation><mixed-citation xml:lang="en">Victor D.W. 3rd, Monsour H.P. Jr., Boktour M., Lunsford K., Balogh J., Graviss E.A., Nguyen D.T., McFadden R., Divatia M.K., Heyne K., Ankoma-Sey V., Egwim C., Galati J., Duchini A., Saharia A., Mobley C., Gaber A.O., Ghobrial R.M. Outcomes of liver transplantation for hepatocellular carcinoma beyond the university of California San Francisco criteria: a single-center experience. Transplantation. 2020; 104 (1): 113– 121. https://doi.org/10.1097/TP.0000000000002835.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzaferro V., Llovet J.M., Miceli R., Bhoori S., Schiavo M., Mariani L., Camerini T., Roayaie S., Schwartz M.E., Grazi G.L., Adam R., Neuhaus P., Salizzoni M., Bruix J., Forner A., De Carlis L., Cillo U., Burroughs A.K., Troisi R., Rossi M., Gerunda G.E., Lerut J., Belghiti J., Boin I., Gugenheim J., Rochling F., Van Hoek B., Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009; 10 (1): 35–43. https://doi.org/10.1016/S1470-2045(08)70284-5.</mixed-citation><mixed-citation xml:lang="en">Mazzaferro V., Llovet J.M., Miceli R., Bhoori S., Schiavo M., Mariani L., Camerini T., Roayaie S., Schwartz M.E., Grazi G.L., Adam R., Neuhaus P., Salizzoni M., Bruix J., Forner A., De Carlis L., Cillo U., Burroughs A.K., Troisi R., Rossi M., Gerunda G.E., Lerut J., Belghiti J., Boin I., Gugenheim J., Rochling F., Van Hoek B., Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009; 10 (1): 35–43. https://doi.org/10.1016/S1470-2045(08)70284-5.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzaferro V., Sposito C., Zhou J., Pinna A.D., De Carlis L., Fan J., Cescon M., Di Sandro S., Yi-Feng H., Lauterio A., Bongini M., Cucchetti A. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018; 154 (1): 128–139. Epub 2017 Oct 5. https://doi.org/10.1053/j.gastro.2017.09.025.</mixed-citation><mixed-citation xml:lang="en">Mazzaferro V., Sposito C., Zhou J., Pinna A.D., De Carlis L., Fan J., Cescon M., Di Sandro S., Yi-Feng H., Lauterio A., Bongini M., Cucchetti A. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018; 154 (1): 128–139. Epub 2017 Oct 5. https://doi.org/10.1053/j.gastro.2017.09.025.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Castroagudín J.F., Molina-Pérez E., Ferreiro-Iglesias R., Abdulkader I., Otero-Antón E., Tomé S., Varo-Pérez E. Late recur rence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed? Transplant. Proc. 2012; 44 (6): 1565–1567. https://doi.org/10.1016/j.transproceed.2012.05.007.</mixed-citation><mixed-citation xml:lang="en">Castroagudín J.F., Molina-Pérez E., Ferreiro-Iglesias R., Abdulkader I., Otero-Antón E., Tomé S., Varo-Pérez E. Late recur rence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed? Transplant. Proc. 2012; 44 (6): 1565–1567. https://doi.org/10.1016/j.transproceed.2012.05.007.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Bittermann T., Hoteit M.A., Abt P.L., Forde K.A., Goldberg D. Waiting time and explant pathology in transplant recipients with hepatocellular carcinoma: A Novel Study Using National Data. Am. J. Transplant. 2014; 14 (7): 1657–1663. https://doi.org/10.1111/ajt.12774. Epub 2014 Jun 5.</mixed-citation><mixed-citation xml:lang="en">Bittermann T., Hoteit M.A., Abt P.L., Forde K.A., Goldberg D. Waiting time and explant pathology in transplant recipients with hepatocellular carcinoma: A Novel Study Using National Data. Am. J. Transplant. 2014; 14 (7): 1657–1663. https://doi.org/10.1111/ajt.12774. Epub 2014 Jun 5.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Nissen N.N., Menon V., Bresee C., Tran T.T., Annamalai A., Poordad F., Fair J.H., Klein A.S., Boland B., Colquhoun S.D. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient. HPB (Oxford). 2011; 13 (9): 626–632. https://doi.org/10.1111/j.1477-2574.2011.00342.x</mixed-citation><mixed-citation xml:lang="en">Nissen N.N., Menon V., Bresee C., Tran T.T., Annamalai A., Poordad F., Fair J.H., Klein A.S., Boland B., Colquhoun S.D. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient. HPB (Oxford). 2011; 13 (9): 626–632. https://doi.org/10.1111/j.1477-2574.2011.00342.x</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Patel S.S., Arrington A.K., McKenzie S., Mailey B., Ding M., Lee W., Artinyan A., Nissen N., Colquhoun S.D., Kim J. Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States. Int. J. Hepatol. 2012; 2012: 253517. https://doi.org/10.1155/2012/253517</mixed-citation><mixed-citation xml:lang="en">Patel S.S., Arrington A.K., McKenzie S., Mailey B., Ding M., Lee W., Artinyan A., Nissen N., Colquhoun S.D., Kim J. Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States. Int. J. Hepatol. 2012; 2012: 253517. https://doi.org/10.1155/2012/253517</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Unek T., Karademir S., Arslan N.C., Egeli T., Atasoy G., Sagol O., Obuz F., Akarsu M., Astarcioglu I. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. World J. Gastroenterol. 2011; 17 (37): 4206–4212. https://doi.org/10.3748/wjg.v17.i37.4206</mixed-citation><mixed-citation xml:lang="en">Unek T., Karademir S., Arslan N.C., Egeli T., Atasoy G., Sagol O., Obuz F., Akarsu M., Astarcioglu I. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. World J. Gastroenterol. 2011; 17 (37): 4206–4212. https://doi.org/10.3748/wjg.v17.i37.4206</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Baccarani U., Adani G.L., Avellini C., Lorenzin D., Currò G., Beltrami A., Pasqualucci A., Bresadola V., Risaliti A., Viale P.L., Beltrami C.A., Bresadola F. Comparison of clinical and pathological staging and long-term results of liver transplantation for hepatocellular carcinoma in a single transplant center. Transplant. Proc. 2006; 38 (4): 1111–1113. https://doi.org/10.1016/j.transproceed.2006.02.015</mixed-citation><mixed-citation xml:lang="en">Baccarani U., Adani G.L., Avellini C., Lorenzin D., Currò G., Beltrami A., Pasqualucci A., Bresadola V., Risaliti A., Viale P.L., Beltrami C.A., Bresadola F. Comparison of clinical and pathological staging and long-term results of liver transplantation for hepatocellular carcinoma in a single transplant center. Transplant. Proc. 2006; 38 (4): 1111–1113. https://doi.org/10.1016/j.transproceed.2006.02.015</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Abdelfattah M.R., Abaalkhail F., Al-Manea H. Misdiagnosed or incidentally detected hepatocellular carcinoma in explanted livers: lessons learned. Ann. Transplant. 2015; 20: 366–372. https://doi.org/10.12659/AOT.893782.</mixed-citation><mixed-citation xml:lang="en">Abdelfattah M.R., Abaalkhail F., Al-Manea H. Misdiagnosed or incidentally detected hepatocellular carcinoma in explanted livers: lessons learned. Ann. Transplant. 2015; 20: 366–372. https://doi.org/10.12659/AOT.893782.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Mehta N. Hepatocellular carcinoma—how to determine therapeutic options. Hepatol. Commun. 2020; 4 (3): 342–354. https://doi.org/10.1002/hep4.1481</mixed-citation><mixed-citation xml:lang="en">Mehta N. Hepatocellular carcinoma—how to determine therapeutic options. Hepatol. Commun. 2020; 4 (3): 342–354. https://doi.org/10.1002/hep4.1481</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Zeair S., Rajchert J., Stasiuk R., Cyprys S., Miętkiewski J., Zasada-Cedro K., Karpińska E., Duczkowska M., Parc zewski M., Wawrzynowicz-Syczewska M. Recurrence of hepatocellular carcinoma after liver transplantation: a single-center experience. Ann. Transplant. 2019; 24: 499–505. https://doi.org/10.12659/AOT.918150</mixed-citation><mixed-citation xml:lang="en">Zeair S., Rajchert J., Stasiuk R., Cyprys S., Miętkiewski J., Zasada-Cedro K., Karpińska E., Duczkowska M., Parc zewski M., Wawrzynowicz-Syczewska M. Recurrence of hepatocellular carcinoma after liver transplantation: a single-center experience. Ann. Transplant. 2019; 24: 499–505. https://doi.org/10.12659/AOT.918150</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
